

WHAT IS THE MIDAS 2 TRIAL?

The MIDAS2 study is looking for people who have severe persisting fatigue after stroke.


The study will test whether the wakefulness medication called **Modafinil** taken for 56 days is safe and can alleviate stroke-related fatigue in a much larger group of stroke survivors.

FATIGUE:

- affects up to 70% of stroke survivors.
- defined as 'a feeling of early exhaustion with weariness, lack of energy and aversion to effort that develops during physical or mental activity and is usually not improved by rest'.

Participants will receive either 200 mg of modafinil or placebo (an identical tablet with no active ingredients). There is a 50% chance of being in either of these groups.

There are currently 14 hospitals across Australia participating in the study



MORE INFORMATION?

To learn more about this clinical research study and to see if you qualify, please contact study research team:

Claire Tucak

Research Coordinator

Phone: +61 (08) 6457 0200

Email:

claire.tucak@perron.uwa.edu.au



The study is being supported by
The Greater Charitable Foundation.

Study Leaflet_Version 2.0 dated 06 May 2019

MIDAS2 (Modafinil in Debilitating Fatigue After Stroke 2)



Have you had a **STROKE** at least **3 months ago?**

And are you experiencing **severe persisting FATIGUE?**